Loading...
BVMFBIOM3
Market cap169mUSD
Dec 23, Last price  
8.24BRL
1D
6.74%
1Q
-16.77%
Jan 2017
33.32%
Name

Biomm SA

Chart & Performance

D1W1MN
BVMF:BIOM3 chart
P/E
—
P/S
8.84
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
14.26%
Rev. gr., 5y
137.44%
Revenues
118m
+12.62%
6,645,0001,995,0003,017,000608,000877,000000000103,0001,566,0008,944,00058,668,000107,090,000104,954,000118,194,000
Net income
-81m
L-12.34%
6,000-5,318,000-7,412,000-7,016,000-4,273,000-4,675,000-14,140,000-10,059,000-12,713,0008,282,000-45,608,000-38,128,000-42,562,000-55,812,000-70,767,000-80,261,000-92,559,000-81,141,000
CFO
-75m
L+18.71%
-5,715,000-5,310,000-4,640,000-1,784,000-7,103,000-10,508,000-19,784,000-13,899,000-38,281,000-54,405,000-44,115,000-80,852,000-96,874,000-93,784,000-62,999,000-74,785,000

Profile

Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; CONFORT CARE, a moisturizing foot cream; GLARGILIN, a glargine insulin; and HERZUMA, a trastuzumab. Biomm S.A. was founded in 2001 and is based in São Paulo, Brazil.
URL
https://biomm.com/
IPO date
Sep 05, 2002
Employees
Domiciled in
BR
Incorporated in
BR

Valuation

Title
BRL in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
118,194
12.62%
104,954
-1.99%
107,090
82.54%
Cost of revenue
198,009
178,845
170,558
Unusual Expense (Income)
NOPBT
(79,815)
(73,891)
(63,468)
NOPBT Margin
Operating Taxes
340
(630)
475
Tax Rate
NOPAT
(80,155)
(73,261)
(63,943)
Net income
(81,141)
-12.34%
(92,559)
15.32%
(80,261)
13.42%
Dividends
Dividend yield
Proceeds from repurchase of equity
45,000
128,326
11,803
BB yield
-9.36%
-25.04%
-1.30%
Debt
Debt current
47,660
51,060
50,075
Long-term debt
105,940
121,224
134,070
Deferred revenue
Other long-term liabilities
32,366
32,302
45,446
Net debt
91,188
83,027
120,278
Cash flow
Cash from operating activities
(74,785)
(62,999)
(93,784)
CAPEX
(6,222)
(5,439)
(7,442)
Cash from investing activities
(2,857)
(6,160)
61,492
Cash from financing activities
25,559
113,788
7,419
FCF
(64,342)
(77,618)
(89,184)
Balance
Cash
53,738
80,336
55,136
Long term investments
8,674
8,921
8,731
Excess cash
56,502
84,009
58,512
Stockholders' equity
106,584
143,360
95,849
Invested Capital
251,704
279,686
282,664
ROIC
ROCE
EV
Common stock shares outstanding
83,213
75,466
70,063
Price
5.78
-14.87%
6.79
-47.69%
12.98
-19.93%
Market cap
480,971
-6.14%
512,413
-43.65%
909,420
-11.20%
EV
572,159
595,440
1,029,698
EBITDA
(68,335)
(61,640)
(51,844)
EV/EBITDA
Interest
14,954
14,276
14,402
Interest/NOPBT